Follow us : Twitter LinkedIn
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
Client Login
Home > Publications > Search for a publication

Search a publication

Title of Intellectual Property
Patents
European and Unitary Patent
US Patent
Trademark
European Union trademark
International Trademark
Design
Domain names
Software
Copyright
Theme
Health
Medtech
Patentability of Biological Material
Arbitration and Mediation
Contracts
Infringement
Regulation, Labelling
Data
Wine and Spirits
Pharmacy
Well-known TM, Dilution, Use
Accelerated Examination
European patent
Immunotherapy
PACTE Law
Biodiversity
Brexit
Biomarkers
Author name

Search result

14 publications

Mediation? A real strategic choice !

By Frédérique FAIVRE PETIT, Managing Patner, Mediator
Faivre-Petit_search.jpg Choosing mediation is giving yourself real chances to get out of a deadlock, it is giving yourself the means to find common ground under good conditions, so it is quite the opposite of a decision by default, it's a real strategic choice!
Published on: 9th Jun 2021

Brazil: End of the extension of patent validity and special regime for the pharmaceutical sector

By Frédérique FAIVRE PETIT, Managing Partner
Faivre-Petit_search.jpg On May 7, 2021, the Brazilian Supreme Court put an end to the extension of validity of Brazilian patents for a 10-year period starting from the granting of patents, due to the unconstitutionality of the measure. It has now specified the terms of its application, by a new decision issued on May 12, 2021.
Published on: 19th May 2021

Pandemic and european patent application filings in the biomedical field

By Frédérique FAIVRE PETIT, Managing Partner
Faivre-Petit_search.jpg If the European Patent Office (EPO) notes a very slight decrease in the total number of European patent applications filed in 2020 (-0.7%), it nevertheless notes for this pandemic year a strong increase in these filings in the biomedical field.
Published on: 8th April 2021

Brazil: Duration of patent protection under discussion before the Supreme Court

By Frédérique FAIVRE PETIT, Managing Partner.
Faivre-Petit_search.jpg The patent system in Brazil which has guaranteed a term of protection of 10 years from the grant of a Brazilian patent in the event that the Brazilian patent office takes more than 10 years to grant the patent is now being challenged before the Brazilian Supreme Court on the grounds that it is unconstitutional. The issue is scheduled to be decided by the Brazilian Supreme Court on April 7, 2021
Published on: 25th March 2021

A conflict? A relational difficulty? Think mediation!

Frédérique FAIVRE PETIT, Partner, French Patent Attorney & European Patent Attorney
Faivre-Petit_search.jpg Are you an entrepreneur, a head of service, a project coordinator? You need to dedicate yourself to the recovery and development of your activity. You do not have enough time available to settle conflicts, disputes or litigations, more or less important, potential or occurring as a part of your activities. You wish to avoid initiating a legal action.
Published on: 22th Jun 2020

What impact will a BREXIT without a withdrawal agreement as of March 30, 2019, have on your IP assets, in particular patents, trademarks & designs, domain names?

By Christian TEXIER, Frédérique FAIVRE PETIT, Sylvain THIVILLIER, Evelyne ROUX, Partners, Cécile PUECH, Senior Associate and Anne CHANTELOUP, Intellectual Property Lawyer.
CTFFPEVR.PNG UK MPs overwhelmingly rejected the negotiated exit agreement of the EU by 432 votes against 202 on Tuesday January 15, 2019.
Published on: 21th Jan 2019

Isolated Nucleic Acids are no Longer Patentable in Australia

By Frédérique FAIVRE PETIT, Partner
vignette F.FAIVRE-PETIT (3).jpg On 7 October 2015, the High Court of Australia ruled in favour of the non-patentability of isolated nucleic acids.
Published on: 15th Oct 2015

The US patent system (still) requires more than the laws of Nature…

By Frédérique FAIVRE PETIT, Partner
vignette F.FAIVRE-PETIT (3).jpg US patent law is probably one of the most lenient in the world: it provides for no exclusion in principle and requires solely that an invention must be, as a first condition, useful (within the meaning of 35 USC 101) before it is examined from the viewpoint of "conventional" patentability criteria such as novelty and inventive step.
Published on: 28th Jul 2014

Diagnostic Method : Confirmation in the United States of the difficulty in obtaining protection

By Frédérique FAIVRE PETIT, Partner
vignette F.FAIVRE-PETIT (3).jpg On 30 October 2013, the District Court for the Northern District of California (DCNDC) invalidated a patent relating to a diagnostic method, thus confirming the difficulty in protecting this type of invention in the United States.
Published on: 13th Dec 2013

MYRIAD: Over 30 years of practice is being revisited by the United States Supreme Court:Isolated DNA is now longer patentable! Hard times for United States protected biotechnology inventions

Frédérique FAIVRE PETIT, Partner
vignette F.FAIVRE-PETIT (3).jpg The Biotechnology industry has been decidedly mistreated by recent decisions in the US which are disrupting over 30 years of practice concerning the protection of inventions relating to or involving genes. This is creating a great uncertainty about the value of corresponding US patents.
Published on: 1st Jul 2013

Myriad : Second confirmation of patentability of isolated DNA. Will this be the final chapter?

By Frédérique FAIVRE PETIT, Partner
vignette F.FAIVRE-PETIT (3).jpg For the third time, an American Court has decided on patentability of «genes», confirming the previous decision, which reversed the first one…. But let us start from the beginning.
Published on: 19th Sept 2012

Are patents and diagnostic methods compatible? Europe - United States - Canada - Brazil - India - China - Japan - Korea - Australia

By FAIVRE PETIT Frédérique, Partner
vignette F.FAIVRE-PETIT (3).jpg Whereas one might think ideally medicine should one day be able to diagnose everything, this has not been achieved yet, although... The pharmaceutical and diagnosis industries...
Published on: 2nd Jul 2012

The European Patent is doing well… and the draft of the “Unitary” Patent is going forward…

By Frédérique FAIVRE PETIT, Partner, European and French Patent Attorney - Cabinet REGIMBEAU
vignette F.FAIVRE-PETIT (3).jpg In 2010, the number of European patent applications reached the highest level in the Office’s 34 year history, with some 235 000 filings representing an 11% increase on patent applications filed in 2009.
Published on: 27th April 2011

Laws on Bioethics in France

By Frédérique Faivre Petit, French and European Patent Attorney, Partner - Cabinet REGIMBEAU
vignette F.FAIVRE-PETIT (3).jpg Laws on Bioethics were first laid down in France in 1994. The principle then set out by the law-maker was that they should be reviewed after 5 years.
Published on: 4th Sept 2009